L26/P-562 Fertility preservation decision aids for women with cancer: A systematic review
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.895 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von X. Yuan und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What decision aids for fertility preservation exist for women with cancer, and what is their quality and impact on decision-making outcomes? Summary answer Eleven fertility preservation decision aids were identified; quality varied, and meta-analysis showed improved long-term knowledge but no significant effects on decisional conflict or regret. What is known already Cancer and its treatments can impair fertility in reproductive-aged women, and guidelines recommend early counselling and timely referral for fertility preservation. Yet fertility preservation remains underused, partly because decisions are time-sensitive, complex, and preference-sensitive, and oncology consultations may not provide sufficient tailored information. Patient decision aids can support shared decision-making by providing evidence-based option information and value clarification, and have improved decision quality in other clinical contexts. However, fertility preservation decision aids vary in accessibility and quality, and their effects on fertility preservation decision outcomes have not been comprehensively synthesised. Study design, size, duration PRISMA-guided systematic review identifying fertility preservation decision aids for women with cancer. We searched 5 databases from inception to 25 December 2025, plus ClinicalTrials.gov, Google/Google Scholar, the Ottawa Decision Aid Library, and reference lists. Two reviewers independently screened and extracted data. Decision aids were appraised using IPDAS v4; meta-analyses (random-effects) were performed when ≥3 homogeneous studies reported an outcome. Participants/materials, setting, methods Fertility preservation decision aids were eligible if designed for use before/during consultations, provided evidence-based information on ≥ 2 options with risks/benefits, and included value clarification. Effectiveness studies enrolled female cancer patients prior to anticancer treatment and compared decision aids with usual care/control or used pre–post designs. Decision-aid quality was assessed using IPDAS v4; risk of bias was evaluated with RoB 2 (RCTs) and ROBINS-I (non-randomized). Data synthesis used RevMan 5.4.1. Main results and the role of chance From 4,540 database records plus 63 other sources, 18 articles reporting 12 unique fertility preservation decision aids (DAs) met inclusion criteria. Two DAs each were developed in the USA, the Netherlands, and Taiwan, and one each in the UK, Switzerland, Canada, France, Portugal, and Australia. Most DAs were web-based and provided 3-8 FP options; oocyte/embryo cryopreservation appeared in 11/12. Five DAs were publicly accessible and were assessed with IPDAS v4, showing variable overall compliance (48.57%-85.71%); “plain language” scored lowest, while “information disclosure” scored highest. Five unique effectiveness studies (2012–2021; duration 6-12 months) involving 250 women (18-43 years) were meta-analysed. DAs improved long-term FP knowledge (SMD 0.69; 95% CI 0.09-1.29; P=0.02; I²=50%), but not short-term knowledge (SMD 0.73; 95% CI -0.23-1.68; P=0.14; I²=82%). No statistically significant effects were found for decisional conflict (short-term MD -5.54; 95% CI -13.72-2.64; P=0.18; I²=75%; long-term MD -9.86; 95% CI -24.50-4.78; P=0.19; I²=85%) or decisional regret (short-term MD 0.08; 95% CI -0.34-0.49; P=0.72; I²=38%; long-term MD -0.22; 95% CI -0.70-0.26; P=0.36; I²=46%). Limitations, reasons for caution Only 5/12 decision aids were publicly accessible for IPDAS appraisal, and scoring may be subjective despite double-blind rating. Meta-analyses relied on small, mostly non-randomized studies with heterogeneous comparators, limiting causal inference and generalisability. Limited data prevented linking decision-aids quality with outcomes. Wider implications of the findings High-quality, accessible fertility preservation decision aids remain limited, especially for low-literacy and minority populations. Future tools should be culturally adapted for diverse and non-Western settings, developed using standards such as IPDAS, and maintained through partnerships with professional associations to ensure reach, sustainability, and timely evidence updates. Trial registration number Yes
Zitieren
APA
Yuan, X., Shen, Y., Hui, V., & Li, W. (2026). L26/P-562 Fertility preservation decision aids for women with cancer: A systematic review. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.895
Vancouver
Yuan X, Shen Y, Hui V, Li W. L26/P-562 Fertility preservation decision aids for women with cancer: A systematic review. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.895
BibTeX
@article{Yuan2026,
author = {Yuan, X. and Shen, Y. and Hui, V. and Li, W.},
title = {L26/P-562 Fertility preservation decision aids for women with cancer: A systematic review},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.895}
}
EUVIMED